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Abstract 
Background 
Out-of-hospital cardiac arrest (OHCA) is a global public health issue. There is wide variation in both 
regional and inter-hospital survival rates from OHCA and overall survival remains poor at 7%. 
Regionalization of care into cardiac arrest centers (CAC) improves outcomes following cardiac arrest 
from ST elevation myocardial infarction (STEMI) through concentration of services and greater provider 
experience. The International Liaison Committee on Resuscitation (ILCOR) recommends delivery of all 
post-arrest patients of to a CAC, but that randomized controlled trials are necessary in patients without 
ST elevation (STE). 
 
Methods/Design 
Following completion of a pilot randomized trial to assess safety and feasibility of conducting a large-
scale randomized controlled trial in patients following OHCA of presumed cardiac cause without STE, 
we present the rationale and design of A Randomized tRial of Expedited transfer to a cardiac arrest 
center for non-ST elevation OHCA (ARREST). In total 860 patients will be enrolled and randomized 
(1:1) to expedited transfer to CAC (24/7 access to interventional cardiology facilities, cooling and goal-
directed therapies) or to the current standard of care, which comprises delivery to the nearest 
emergency department. Primary outcome is 30-day all-cause mortality and secondary outcomes are 30-
day and 3-month neurological status and 3, 6 and 12-month mortality. Patients will be followed up for 
one year after enrolment.   
 
Conclusion 
Post-arrest care is time-critical, requires a multi-disciplinary approach and may be more optimally 
delivered in centers with greater provider experience. This trial would help to demonstrate if 
regionalization of post-arrest care to CACs reduces mortality in patients without STE, which could 
dramatically reshape emergency care provision. 
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Introduction 
Out-of-hospital cardiac arrest (OHCA) is a global public health issue. Each year there are 28,000 
emergency medical services (EMS)–treated OHCA in England and approximately 330,000 EMS-
attended OHCA in the United States.1,2 There is wide variation in both regional and inter-hospital 
survival rates from OHCA and overall survival remains poor, at 7%.3 The adoption of systematic 
approaches to post-resuscitation care may improve long-term survival from OHCA.4,5 Regionalization of 
care into specialist centers has played a vital role in the management of time-critical illnesses through 
concentration of services and greater provider experience.6-13 Post-resuscitation care in hospitals with 
the facilities to deliver targeted temperature management and treatment of the underlying cause 
through coronary reperfusion is thought to further improve this survival in patients.14 The International 
Liaison Committee on Resuscitation (ILCOR) suggests transport of all post-arrest patients to a cardiac 
arrest center (CAC). It is difficult to conclude which of the components of post-arrest care is essential, 
given the observational nature of studies. In addition to volume and quality of care delivery, it is of 
increasing opinion that CACs should provide 24/7 access to interventional cardiology facilities, targeted 
temperature management, diagnostic imaging capability and standardized neuroprognostication (Table 
1).15-18 Coronary artery disease is responsible for >70% of OHCA, with an acute occlusion 
demonstrated in 50% of consecutive patients taken immediately to coronary angiography.19 There is 
expert consensus that early reperfusion therapy in ST-elevation (STE) reduces mortality.20,21 Patients 
without STE however are a heterogeneous group, with an emphasis placed on prior rule out of non-
coronary causes.21 Due to the lack of randomized data, there has been variable uptake of an early 
reperfusion strategy amongst the interventional cardiology community. Last year, in London, of the 2393 
patients with OHCA and ROSC sustained to hospital, approximately two thirds were delivered to a non-
CAC (1520/2393; 63.5%). Of these patients we estimate that between 2 and 4% were transferred to a 
CAC following index admission to a non-CAC (Table 2). ILCOR states that randomized trials are 
therefore essential in this population to determine if timely delivery to a CAC improves survival.22 
However, the coordination of this is complex and close interaction is necessary between centers and 
ambulance services and internally between the emergency department, cardiologists and the critical 
care team. There is an urgent need for randomized control data examining the benefits of early delivery 
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of post-cardiac arrest care in specialist centers, specifically in the absence of STE. Post-arrest care is 
time-critical, requires a multi-disciplinary approach and may be more optimally delivered in centers with 
greater provider experience.  Following completion of a pilot randomized trial to assess safety and 
feasibility of conducting a large-scale randomized controlled trial in patients without STE, we present the 
rational and design of A Randomized tRial of Expedited transfer to a cardiac arrest center for non-ST 
elevation OHCA (ARREST). 23 
 
 
 
Table 1. Important components of a cardiac arrest center providing specialist services and 
interventions. *revascularization strategies can include percutaneous coronary intervention and 
coronary artery bypass grafting. 
 
 
 
Specialty Services and interventions 
General Standardized post-resuscitation protocol 
Critical Care Airway management and ventilatory support 
 Hemodynamic and renal support 
 Acid-base, electrolyte and glucose control 
 Targeted temperature management 
Cardiothoracic Echocardiography 
 Immediate coronary angiography and revascularization strategies* 
 Mechanical circulatory support 
 Electrophysiology and heart failure specialist input ± device insertion 
Radiology 24 hour imaging and interpretation including computed tomography to rule in/out respiratory or neurological causes 
Neurology Seizure control 
 Standardized multimodality neuroprognostication (including neurophysiology testing) 
 Physiotherapy and referral to neurorehabilitation services 
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Hospital Number and proportion of patients  
Non-Cardiac Arrest Center 1520 63.5% 
Cardiac Arrest Center 873 36.5% 
Total 2393 100% 
 
Table 2. Destination hospital: CAC versus non-CAC.  
This table demonstrates data from 2016-2017 with respect to the destination hospital (CAC versus non-
CAC) of patients who would meet current criteria for inclusion the ARREST trial (no-ST elevation, adult 
cardiac arrest, return of spontaneous circulation). Where n is the number of patients with the desired 
characteristic and N is the total number, the proportion of patients is presented as a %). It can be seen 
from this table that of the patients that fulfil current inclusion criteria for the trial, approximately two thirds 
were delivered to a non-CAC. Of these patients we estimate from the data we have extracted that 
thereafter, roughly 2 to 4% are transferred to a CAC. As this data was not collected prospectively this is 
the best estimate that can be provided based on the assumption that patients were not transferred after 
their index admission to a non-CAC if (i) patient death was recorded at <24 hours and (ii) if the source 
of survival data was the non-CAC (if the patient was transferred to a CAC the survival data would have 
been provided by the CAC). 
 
Methods 
Trial Design 
ARREST is a multi-center randomized controlled trial being conducted in 30 hospitals in London, United 
Kingdom. Of these, 7 hospitals provide 24/7 access to interventional cardiology with specialist intensive 
care facilities (hereafter referred to as CAC, Table 1) and 27 hospitals have emergency departments 
(Figure 1). The aim is to determine the best post-resuscitation care pathway for patients with arrest of 
presumed cardiac cause but without STE on the post-resuscitation electrocardiogram (ECG). We 
propose that changes to emergency management comprising expedited delivery to a CAC with 
organized post-cardiac arrest care including immediate access to reperfusion therapy (intervention arm) 
will reduce mortality in patients without STE. We propose minimum criteria for a cardiac arrest center in 
Table 1. The intervention arm will be compared to the current standard of care (control arm), which 
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comprises protracted pre-hospital management of the patient without definitive care plan and delivery to 
geographically closest emergency department, which could potentially delay both transfer times to 
hospital and appropriate post-resuscitation care delivery. Patients will be followed up for one year. The 
trial will conform to the declaration of Helsinki, and in accordance with the Good Clinical Practice 
guidelines.  Due to the emergency nature of the trial and the immediacy of the intervention, the need for 
prior informed consent has been waived.24 If the patient regains capacity following the cardiac arrest, 
informed consent should be gathered once the initial emergency has passed. 25,26 The trial was granted 
ethical approval by the National Research Ethics Committee (REC 13/LO/1508) in January 2014. The 
trial is sponsored by King’s College London, UK and has received charitable funding for the entire trial 
from the British Heart Foundation CS/16/3/32615. The authors are solely responsible for the design and 
conduct of this study; all study analyses, the drafting and editing of the paper and its final contents. The 
trial is registered with International Standard Randomized Controlled Trials www.ISRCTN.com (ISRCTN 
96585404). No extramural funding was used to support this work. The authors are solely responsible for 
the design and conduct of this study; all study analyses, the drafting and editing of the paper and its 
final contents. 
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Figure 1. ARREST Trial receiving hospitals 
Map of London demonstrating the receiving hospitals in the ARREST trial, there are 3 participating 
hospitals in total (correct as of June 2018), 7 of these are CAC (3 CAC do not have EDs). 28 hospitals 
have emergency departments including 4 CACs. CACs are denoted on the map as a red heart. 
Abbreviations: Char X Charing Cross Hospital, UCH University College London Hospital 
 
Primary research question 
A post-resuscitation care pathway comprising pre-hospital triage and immediate strategic delivery of the 
post-cardiac arrest patient of presumed cardiac cause (Table 3) without STE to dedicated CAC, with 
specialist cardiac resuscitation facilities and access to rapid evaluation and treatment including 
reperfusion will reduce all-cause mortality at 30 days. 
 
Inclusion Exclusion 
Out-of-hospital cardiac arrest 
Criteria for ST-elevation myocardial infarction  (STEMI) on 12-Lead 
electrocardiogram 
Return of spontaneous circulation Do Not Attempt Resuscitation (DNAR) Order 
Age 18 or over (known or presumed) Cardiac arrest suffered after care pathway set and patient en route 
Absence of non-cardiac cause (trauma, drowning, suicide, drug overdose) Suspected pregnancy 
 
Table 3.  Inclusion/exclusion criteria.  
Participants must have fulfil all of the inclusion criteria. Patients will be excluded if they meet any of the 
exclusion criteria. “Cardiac arrest after care pathway set and patient en route” refers to patients who did 
not present with a cardiac arrest in whom a diagnosis has been made pre-hospital by the paramedic 
staff and a decision has been made with regard to definitive treatment. If such patients arrest en-route 
to hospital, they will not be considered eligible for the trial as this may compromise clinical care delivery. 
 
Secondary research questions 
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These are as follows: 1) Neurological status at discharge and 3 months and 2) All-cause mortality at 3, 
6, 12 months. Patients are therefore followed up at 30 days, 3, 6 and 12 months, see Figure 2. 
 
Figure 2 Trial flow diagram 
Study Participants 
Patients with confirmed cardiac arrest of presumed cardiac cause will be assessed for eligibility by the 
attending London Ambulance Service (LAS) paramedic. Inclusion and exclusion criteria are provided in 
Table 3. Due to the emergency context of the research, identification cannot be performed in advance. 
 9 
Patients who re-arrest after they have been randomized into the trial will not be excluded and will be 
conveyed to an emergency department (ED) or CAC as indicated by their treatment allocation. If the 
patient re-arrests on scene and there is recognition of life extinct by the attending paramedic after 
randomization, the patient will not be transferred to an ED or CAC. The patient will remain in the trial 
and patient data will be collected. The trial opened to enrollment in January 2018, and the first patient 
was randomized on February 2, 2018 with recruitment of all patients planned by end of September 
2020. Follow-up of all patients is expected by September 2021 (Figure 3) and reporting of results is 
expected by the end of April 2022.  
 
Figure 3. Enrollment graph for ARREST trial 
Projected enrollment is depicted as a gray line and actual enrolment is depicted as a purple line. The 
trial opened to recruitment in January 2018 and the first patient was enrolled in February 2018.  
 
Randomization 
Designated LAS staff at the Advanced Paramedic Practitioner (APP) dispatch desk will randomize 
patients into the intervention arm or control arm (current standard of care and delivery to the nearest ED 
where possible) using the following procedure: LAS paramedics attending a suspected OHCA of 
presumed cardiac cause will assess the patient for eligibility (Table 3). Once eligibility is confirmed, the 
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on-site paramedic will contact the APP desk to randomize the patient. The APP desk staff will access 
the online randomization website (www.sealedenvelope.com), enter the required details, and generate 
a study ID and treatment allocation. Patients will be randomized either to an expedited transfer to a 
CAC or to receive standard of care with delivery to the nearest ED where possible. The APP desk will 
inform the on-site paramedic which group the patient has been randomized to, and the on-site 
paramedic will proceed as appropriate. The APP desk will provide the necessary information to the 
Clinical Audit and Research Unit at LAS for them to track the patient report form to obtain clinical data. 
Due to the radical difference between the interventions in the two study arms, the study cannot be 
blinded. 
 
Trial Treatments 
Intervention arm 
The intervention arm consists of activation of the pre-hospital triaging system currently in place for post-
arrest STEMI patients. This involves pre-alert of the CAC and strategic delivery of the patient to the 
cardiac catheter laboratory (24 hours a day, 7 days a week) with a view to immediate coronary 
angiography+/- PCI. The final decision to perform CA+/-PCI remains with the Interventional cardiologist 
responsible for the patient. Patients will receive definitive post-resuscitation care: intubation and 
ventilation, targeted temperature management, and goal-directed therapies where necessary, including 
evaluation and identification of underlying cause of arrest with access to immediate reperfusion if 
necessary as per current guidelines. Neuro-prognostication will occur no earlier than 72 hours post-
cardiac arrest to prevent premature withdrawal of life-sustaining treatment. Transfer times estimated 
from the 40-patient pilot are anticipated to be 100 minutes (median; IQR 75 to 113) from time of arrest 
to the designated center. 
 
Control arm 
The control arm comprises the current standard of pre-hospital advanced life support care management 
for patients with return of spontaneous circulation (ROSC) following cardiac arrest of suspected cardiac 
etiology. If the patient survives, they will be conveyed to the geographically closest emergency 
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department. Management thereafter will be as per standard hospital protocols however as in the 
intervention arm, delayed neuro-prognostication is recommended in trial patients.  
 
Crossover 
The likelihood of crossover is anticipated to be low in patients with ROSC in the absence of STE on the 
ECG. If a clinical decision is made either by the paramedic staff or the in-hospital care team that the 
patient in the control arm (current standard of care and delivery to the nearest ED) should receive 
urgent coronary angiography, this will not be considered crossover. Extensive paramedic training has 
been provided to prevent inappropriate crossover, however if this does happen the patient will remain in 
the trial (in the arm they were randomly assigned to) as part of the intention to treat analysis. 
 
Trial Procedures and Data Collection 
Trial procedure summary, data collection and follow-up are summarized in Table 4. The research 
paramedics at LAS will collect pre-hospital data from the LAS patient documentation (patient report 
form, PRF) prior to patient consent. If the patient dies before consent is obtained research paramedics 
will also collect mortality data. If the patient is delivered to hospital, designated research nurses will 
collect data for in-hospital stay and the 30-day, 3, 6 and 12-month follow-up time points. All patient 
information will then be entered online into an electronic case report form provided by 
www.sealedenvelope.com.  Full details of the information collected are provided in the supplementary 
material. 
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  Pre-
hospital 
On arrival 
to hospital In hospital 30 days 3 months 6 months 12 months 
Review of eligibility criteria X 
  
       
ROSC assessment X X 
 
       
Randomization X           
Transfer to CAC or hospital X       
PIS & Informed consent / 
Personal Consultee / 
Professional Consultee 
  
X        
Neurological status  X X  X   
Mortality status 
 
X X X X X X 
EQ-5D-5L     X    
 
Service use questionnaire   X  X   
SAE / NSAEs X X X X X 
  
 
Table 4 Summary of trial procedures and follow up 
 
Outcomes 
The primary outcome is 30-day all-cause mortality. The primary and secondary outcomes are reported 
in table 5. 
 
Primary Outcome Secondary Outcomes 
 
All-cause mortality at 30 days 
 
Neurological status at discharge and 3 months  
All-cause mortality at 3, 6 and 12 months  
EQ-5D-5L at discharge 
 
Table 5: Primary and secondary outcomes 
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Statistical Considerations  
Sample size  
Mortality at 30 days in the control arm is expected to be approximately 60% for the cohort of patients 
recruited into ARREST. This figure is based on Pan London OHCA data (87% mortality with ROSC at 
any time post cardiac arrest and 73% mortality with ROSC maintained to hospital), registry data and the 
pilot randomized trial (50% overall mortality). Observational studies on implementation of treatment 
bundles have shown absolute risk reductions (ARR) of near 30% compared to the comparator group 
and in the PROCAT registry an ARR of 16% was shown following PCI in post-arrest patients of 
presumed cardiac cause without STE.12,27,28 A trial of 860 patients (430 in each arm) will provide 80% 
power to detect an absolute reduction of 10% (i.e. 60% to 50%) including 10% loss to follow-up and a 
5% significance level. If the mortality is higher than 60% then the power will increase to detect a 10% 
absolute reduction in mortality. 
 
Statistical Analysis 
A detailed statistical analysis plan will be produced prior to any analysis of the data by treatment 
groups. The primary analysis will be a comparison of all-cause mortality 30 days after randomization 
between the two arms. A risk difference in all-cause mortality at 30 days together with a 95% 
confidence interval and p-value will be calculated together with the risk ratio. Similarly, these analyses 
will be undertaken for all-cause mortality at 3, 6 and 12 months. Kaplan-Meier curves will be produced 
to show all-cause mortality to 30 days and to 12 months. Hazard ratios will be presented from Cox 
proportional hazards modelling. Neurological status will also be compared at 3 months using the 
modified Rankin Score (an ordinal score from 1 (normal neurological status) to 6 (dead) available at 
www.modifiedrankin.com (Table 6). Ordered logistic regression will be used to compare the two 
treatments and a trend test computed. Intention-to-treat analysis will be performed as the primary 
statistical method; this includes all randomized patients in the groups to which they were randomly 
assigned, regardless of their adherence with the entry criteria, treatment they actually received and 
deviation from the protocol.  Two-sided p-values will be used for all superiority testing. All statistical 
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analyses shall be performed using Stata® software (Stata Corp. LP). A limited number of pre-planned 
subgroup analyses on the primary endpoint will be undertaken which will be detailed in the statistical 
analysis plan. Analyses will be undertaken using logistic regression and a formal test undertaken by 
including an interaction term between the characteristic and the intervention. 
 
 
Modified Rankin Score Neurological Outcome 
0 No symptoms 
1 No significant disability. Able to carry out all usual activities, despite some symptoms 
2 
Slight disability. Able to look after own affairs without assistance but unable to carry out all previous 
activities 
3 Moderate disability. Requires some help but able to walk unassisted 
4 
Moderately severe disability. Unable to attend to own bodily needs without assistance and/or unable to 
walk unassisted 
5 Severe disability. Requires constant nursing care and attention, bedridden, incontinent 
6 Dead 
 
Table 6. The modified Rankin Score and the associated neurological outcome 
(www.modifiedrankin.com) 
 
Health economic evaluation 
This will compare the relative cost and cost-effectiveness of intervention arm to the control arm. Primary 
economic evaluation will be a cost effectiveness analysis (CEA) based on all-cause mortality at 30 
days. The secondary economic evaluation will be a cost utility analysis (CUA) based on Quality 
Adjusted Life Years (QALYs) derived from health utility data collected using the EQ-5D-5L conducted 
on 3-month follow-up data. This will take a primarily health and social care perspective.29  Service use 
data, collected using an adapted Client Service Receipt Inventory (CSRI) will comprise 1) hospital 
admission – including days in intensive care and coronary care 2) procedural cost (laboratory tests, 
reperfusion therapies, device implantation 3) rehabilitation costs including contact with community 
professionals, informal care and sick days due to illness. Service use measured will be combined with 
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nationally applicable unit costs to derive total costs. 30,31 Intervention costs will be estimated using 
micro-costing of all resources used for both the intervention and control, using a non-parametric 
bootstrap regression model to account for non-normal distribution of cost data. 32Cost-effectiveness 
plane (CEP) and cost-effectiveness acceptability curves (CEAC) will be generated. For the CEP, a joint 
distribution of incremental mean costs and effects for the two strategies will be generated using non-
parametric bootstrapping, and plotted against each other. This then shows the probability that the 
intervention arm has 1) higher costs and better outcomes, 2) higher costs and worse outcomes, 3) 
lower costs and worse outcomes, or 4) lower costs and better outcomes than control. CEACs are used 
to explore the probability that each of the treatments is the optimal choice, subject to a range of possible 
maximum values (ceiling ratio) that a decision-maker might be willing to pay for an additional QALY 
gained. 33 
 
 
Limitations 
Bias 
The major sources of bias in this study are differential loss to follow up, lack of blinding and subsequent 
assessment of outcome. In order to reduce the impact of these potential biases, patients in the two 
arms will be treated as equally as possible, including consent process and follow up. A further limitation 
and potential source of bias could arise from the inpatient care following the delivery of a control arm to 
the nearest ED in a CAC, which is possible in 4 of the 7 CACs in London. This will be addressed by 
ensuring the control arm receive the care they would normally receive. We do not anticipate bias to 
affect primary outcome of all-cause mortality.  
 
Control arm crossover to intervention 
Crossover is defined as a patient receiving a pre-hospital care pathway different to the treatment 
allocation. This likelihood is reduced post-ROSC in the absence of STE on the ECG. A 10% crossover 
and loss to follow up has been incorporated into the sample size calculation. If a clinical decision is 
made either by the in-hospital care team that the patient in the control arm (nearest ED) should receive 
urgent coronary angiography, this will not be treated as crossover, and is clarified in the control arm 
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group. Extensive paramedic training will be in place to prevent contamination of the control group 
pathway. If patients in the control arm are delivered to an emergency department in a CAC (nearest 
hospital) we anticipate their pre-hospital course to be less time-sensitive thus affecting post-arrest care.  
 
Potential Risks and Early Stopping 
The potential risk is that of patients with a non-cardiac cause of arrest who are exposed to the 
intervention. This risk will be minimied by exclusion of obvious non-cardiac cause during eligibility 
assessment. One patient in the pilot was found to have a non-cardiac cause of arrest and this patient 
did not survive to hospital.23 30-day all-cause mortality will enable identification of such risk with Data 
Monitoring Committee (DMC) interim analysis. A fully independent DMC has been established to 
monitor the safety of patients in the trial and a detailed Data Monitoring Charter has been developed. 
The sample size will not be adjusted to account for interim analyses; however stringent guidelines will 
be used for the stopping criteria for a benefit of the intervention. 7 The trial will be terminated if there is 
substantial evidence of a benefit of the intervention or clear evidence of an increased mortality risk 
compared to control. The DMC will also monitor recruitment and make recommendations if the 
recruitment target becomes unlikely in the projected recruitment phase. If the required number of 
patients is completed in advance of estimated recruitment time then the trial may be completed ahead 
of schedule depending on the event rates observed. Alternatively, if resources are available recruitment 
may continue in order to maximise the power of the trial.   
 
Discussion 
There are no randomized controlled trial data demonstrating that time critical delivery to a CAC for 
definitive care improves survival. Survival following OHCA remains extremely poor and the 
management of patients without STE is controversial. There is an urgent need for randomized data 
examining the benefits of urgent delivery of post-cardiac arrest care in specialist centers, specifically in 
the absence of STE. Post-arrest care is time-critical, requires a multi-disciplinary approach and may be 
more optimally delivered in centers with greater provider experience. This trial would help demonstrate 
if regionalization of post-arrest care to specialist centers reduces mortality in patients without STE thus 
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has the potential to dramatically reshape emergency care provision. Therefore, either supporting or 
refuting the current drive, in the lack of randomized data, to immediately transport all post-arrest 
patients with presumed cardiac cause to a CAC. Outside of the UK, there are now five trials planned or 
open to recruitment examining the safety, feasibility and timing specifically of reperfusion therapy 
(immediate coronary angiography ± percutaneous intervention in post-ROSC patients without STE 
(Table 7). This trial does not conflict with these because we aim to examine time-critical delivery to a 
specialist center for urgent evaluation, and definitive treatment that includes but is not limited to 
immediate access to reperfusion if necessary.  
Trial Name Chief 
Investigator 
Condition Primary 
Research 
Question 
Intervention Treatment 
Arm 
Control 
Arm 
Primary 
Endpoint 
Sample 
size 
Recruitment 
status 
Coronariography 
in Put of 
hosPital Cardiac 
arrEst (COUPE); 
NCT 02641626 
Ana Viana 
Tejedor, 
Hospital 
Clinico San 
Carlos, 
Spain  
Post-
ROSC 
cardiac 
arrest, no 
ST 
elevation 
on ECG 
RCT to 
evaluate 
the 
efficacy of 
urgent 
versus 
deferred 
CAG 
CAG Urgent 
CAG 
Deferred 
CAG post 
extubation 
with CPC 
1 or 2 
Survival with 
CPC ½: 30 
days and 6 
months 
MACE at 30 
days and 6 
months 
166 Not open to 
recruitment 
Direct or 
Subacute 
Coronary 
Angiography for 
Out-of-hospital 
Cardiac Arrest 
(DISCO); 
NCT02309151 
Sten 
Rubertsson, 
Uppsala 
University 
hospital; Leif 
Svensson, 
Stockholm 
South 
General 
hospital, 
Sweden 
Post-
ROSC 
cardiac 
arrest, no 
ST 
elevation 
on ECG 
RCT to 
evaluate 
the safety 
of urgent 
(<120mins) 
CAG 
CAG Urgent 
CAG<120 
mins 
CAG 
avoided 
within the 
first 3 
days 
Care 
deviations 
affecting 
safety; Pre-
hospital 
timeframes; 
Logistical 
randomisation 
problems; 
Circulatory 
assessment 
120 Currently 
recruiting 
Cardiac 
Catheterisation 
in Cardiac 
Arrest; NCT 
02587494 
Shahar Lavi, 
London 
Health 
Sciences 
Centre, 
Ontario, 
Canada 
Post-
ROSC 
cardiac 
arrest, no 
ST 
elevation 
on ECG, 
VT/VF 
Pilot: to 
evaluate 
the 
efficacy of 
early 
versus late 
(or no) 
CAG 
CAG Early CAG 
(<12 
hours) 
Late or no 
CAG (>24 
hours) 
Composite of 
death and 
CPC 3-5 
75 Not open to 
recruitment 
Early Coronary 
Angiography 
Versus Delayed 
Coronary 
Angiography 
(PEARL); 
NCT02387398 
Karl Kern, 
University of 
Arizona, 
USA 
Post-
ROSC 
cardiac 
arrest, no 
ST 
elevation 
on ECG 
Pilot RCT: 
to evaluate 
the safety 
and 
efficacy of 
early 
versus late 
CAG 
CAG Early CAG 
<120mins 
from ED 
admission 
Late or no 
CAG (>6 
hours) 
Safety 
(MACE) and 
efficacy of 
CAG at 
180days 
240 Currently 
recruiting 
EMERGEncy 
versus delayed 
coronary 
angiogram in 
survivors of out-
of-hospital 
cardiac arrest 
with no obvious 
non cardiac 
cause of arrest  
(EMERGE); NCT 
Christian 
Spaulding, 
Hôpital 
Européen 
Georges 
Pompidou, 
Paris, 
France 
Post-
ROSC 
cardiac 
arrest, no 
ST 
elevation 
on ECG, 
on 
obvious 
non-
cardiac 
cause 
RCT to 
evaluate 
the 
superiority 
of early 
versus 
delayed 
CAG 
CAG Urgent 
CAG 
Delayed 
CAG (48-
72 hours) 
180 day 
survival with 
CPC 1 or 2 
970 Currently 
recruiting 
Table 7 Trials currently recruiting or planning to open to recruitment examining the role of early versus 
delayed coronary angiography in cardiac arrest survivors without STE. 
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